Compare MNKD & PSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNKD | PSEC |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2004 | N/A |
| Metric | MNKD | PSEC |
|---|---|---|
| Price | $3.92 | $2.20 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 8 | 1 |
| Target Price | ★ $8.69 | $2.50 |
| AVG Volume (30 Days) | 4.9M | ★ 5.1M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 20.07% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,966,000.00 | N/A |
| Revenue This Year | $35.81 | N/A |
| Revenue Next Year | $11.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $2.11 |
| 52 Week High | $6.51 | $3.50 |
| Indicator | MNKD | PSEC |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 39.13 |
| Support Level | $3.30 | $2.15 |
| Resistance Level | $3.94 | $2.82 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 80.13 | 7.61 |
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.